V28 Changed the Value Map
When CMS-HCC V28 reached 100% implementation on January 1, 2026, it restructured which diagnoses generate meaningful risk score impact. Over 2,000 ICD-10 codes lost their HCC mappings entirely. Coefficients shifted across the remaining categories. Conditions that retrospective programs had prioritized for years because of their high RAF value under V24, such as vascular disease and specified arrhythmias, now generate significantly less return. Conditions tied to genuine clinical complexity, such as chronic kidney disease and heart failure, gained relative weight.
For retrospective programs, this means the playbook needs rewriting. Chase lists built on V24 priorities are directing coders to conditions that no longer justify the review effort. Productivity metrics calibrated to pre-V28 economics overstate the value of each chart review. Revenue projections based on historical RAF uplift rates are unreliable because the per-code value has shifted.
What Still Works
Retrospective chart review remains necessary. Providers will always underdocument. Codes will always be missed during initial claims processing. Plans will always need a reconciliation process to capture legitimate complexity that the front-end workflow didn’t catch.
What works under V28 is retrospective review that targets the conditions V28 values most. Well-documented chronic conditions with clear MEAT evidence. Diagnoses tied to genuine clinical complexity that carry meaningful coefficients under the new model. Conditions where the documentation is strong enough to survive not just submission but audit scrutiny.
Two-way review also works better under V28 than it did under V24. Because each remaining HCC carries more relative weight, the compliance value of removing an unsupported code is proportionally greater. A single unsupported diagnosis has a larger impact on audit outcomes when fewer total codes contribute to the risk score. Programs that clean their submissions through deletion protect a larger share of their risk-adjusted revenue.
What Doesn’t Work Anymore
High-volume, low-precision chart review is the biggest casualty of V28. Programs that process thousands of charts looking for any submittable code, regardless of documentation quality or clinical significance, generate diminishing returns under the new coefficient structure. The effort per chart stays the same. The revenue per code dropped for many of the categories these programs targeted.
Add-only methodology was already under regulatory pressure before V28. The DOJ’s $117.7 million Aetna settlement (March 2026) and $556 million Kaiser settlement targeted add-only programs. OIG’s February 2026 guidance named add-only reviews as high-risk. V28 compounds the problem by reducing the financial return from the very codes these programs are structured to chase. The economics and the compliance risk now both argue against one-directional review.
Chart review disconnected from clinical care is losing its foundation. CMS finalized the exclusion of unlinked chart review diagnoses for CY 2027. Diagnoses identified through retrospective review that can’t be tied to an encounter will no longer generate risk score credit. Programs built around finding codes in historical charts without linking them to encounters are watching their output lose value as a matter of policy.
Rebuilding for the V28 Era
Retrospective Risk Adjustment under V28 requires updated chase list prioritization aligned to new coefficients, two-way review that adds supported codes and removes unsupported ones, MEAT validation built into every chart review, and encounter linkage for every submitted diagnosis. Programs that restructure around these requirements will find that V28 rewards accurate, well-documented coding more consistently than V24 did. The model penalizes volume. It rewards precision. Programs designed for precision will outperform programs designed for volume from this point forward.
